LIVE
Real-Time
NEWS MONITOR
--:--:--
⬤ LOW 04 Jul 2026, 01:15 UTC

Johnson & Johnson Is Walking Away From a $100 Billion Obesity Market. Could That Actually Make It the Better Long-Term Buy Than Eli Lilly?

Johnson & Johnson doesn't need GLP-1 drugs to grow, and that's good news for long-term investors.
ECONOMY MARKETS
\
↗ Read Full Story ← Back to Monitors
Share: Twitter/X LinkedIn
Latest in Markets
⬤ LOW
R R Kabel enters optical fibre cable segment with ₹77 crore U M Cables acquisition
CNBC TV18 - Business · 4 min ago
⬤ CRITICAL
Pope Leo warns in France that AI is creating ’paradise of machines’
Investing.com · 5 min ago
⬤ LOW
Himadri Speciality, Borosil Renewables among 5 fundamental stock picks Ambareesh Baliga recommends buying for short term
Mint - Markets · 6 min ago
⬤ LOW
XCF Global reports $10M August renewable diesel revenue
Investing.com · 7 min ago
⬤ LOW
Abeona Therapeutics stock reiterated at Buy by H.C. Wainwright
Investing.com · 8 min ago
Terms of Service